Biotech Week Ending May 4: Choppy Action Persists-Risk Off…Update-3
Traders -look for a turnaround in small cap biopharma and medtech today. NAZ at 7890. 5/10 1:30p EDT....Well we know now that even biotech stocks are not immune to tariffs. Risk off. Major ETFS IBB at 104.5 and XBI near 84 are at intermediate support and off lows for the week. But despite a bad...
Biopharma Wrap-Up Q1 2019: Large Caps Lag Since August 2018
Biopharma Wrap-Up: Sideways to Neutral in Active Trading for Quarter Biopharma stocks ended the quarter in a snooze as investors took a wait and see attitude as earnings roll-out for large caps. The IBB was off 0.83% today to $106.42 and up 9% QTD. The XBI is still up 19.65% QTD but in a...
Large Cap Biopharma Performance and Valuations 4/28/19
Large Cap Biopharma Stocks: Performance and Valuations for 2019. In 2019 the IBB was a less risky pick for a biopharma portfolio; ABBV and BMY look good. Merck (MRK) and Vertex (VRTX) were the top winners since 1/15/18. There was a severe correction in biopharma stocks two weeks ago so these...
Large Cap Biopharma Stocks Performance 2019: Interim Report 4/25
Large Cap Biopharma Stocks Review Ongoing Through Q1 Earnings Small and Mid-Caps Outperform Large Caps YTD: XBI up 21 % YTD vs IBB up 8.19% QQQ up 27%. Rally emerging today on oversold condition in biotech. We will update this valuation review since the political onslaught and sell-off from...
Biotech Wreck: What To Look For Next…Update-3 earnings reports
Update-3 XLV up from bottom at $86 to $88.63. IBB holding but more choppy at $107 level. Update-2 12p EDT-IBB flattish at $106 as earnings on large caps come in-will be reviewed at end of week. ABBV down 0.8% on Humira concerns:, profit forecast raised EPS gains 14.4%, Revenues gain 0.4%. BMY...